4LL Stock Chart & Stats
CHF7.52
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF7.52
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF5.07 - CHF12.00
Previous CloseN/A
Volume0.00
Average Volume (3M)78.00
Market Cap
CHF903.14M
Enterprise ValueCHF1.80K
Total Cash (Recent Filing)CHF774.35M
Total Debt (Recent Filing)CHF1.04B
Price to Earnings (P/E)―
Beta-1.87
Next Earnings
Oct 28, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume78
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.89
Price to Sales (P/S)0.49
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.26Price Target Upside-16.79% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)-0.69
Revenue Forecast (FY)CHF1.93B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And LiquidityPositive operating and free cash flow provide internal funding for product investment, reduce reliance on external financing, and improve resilience while profitability remains under development. The substantial cash balance also offers flexibility to manage the business transition.
Integrated Care Scale And Margin ExpansionIntegrated Care combines very broad member reach with improving profitability, suggesting better operating leverage in Teladoc’s core platform. Growth in chronic care, international operations, and hybrid models can support a more durable and diversified revenue base.
Connected-care And AI Product InnovationA unified connected-care model and AI-enabled clinical intelligence can deepen customer integration and improve care coordination across conditions. If adoption develops as planned, these products may strengthen differentiation and expand Teladoc’s strategic relevance.
Bears Say
Persistent Losses And Weak Revenue TrendOngoing operating and net losses limit evidence of a self-sustaining earnings model, while declining revenue makes future operating leverage harder to achieve. Although losses have narrowed, sustained top-line stabilization is still required before profitability can become durable.
BetterHelp Business-model Transition RiskThe shift from cash-pay acquisition toward insurance may improve long-term market access, but it is currently shrinking revenue and leaving the segment near break-even. Execution, reimbursement, and customer-acquisition changes create material uncertainty over recovery timing.
Provider Capacity Constrains Insurance ConversionInsufficient provider capacity can prevent Teladoc from converting insurance demand into completed sessions and revenue, even after credentialing efforts. Scaling the network across markets requires sustained recruitment and activation, creating an operational constraint on the transition.
Teladoc News
4LL FAQ
What was Teladoc’s price range in the past 12 months?
Teladoc lowest stock price was CHF5.07 and its highest was CHF12.00 in the past 12 months.
What is Teladoc’s market cap?
Teladoc’s market cap is CHF903.14M.
When is Teladoc’s upcoming earnings report date?
Teladoc’s upcoming earnings report date is Oct 28, 2026 which is in 63 days.
How were Teladoc’s earnings last quarter?
Teladoc released its earnings results on Jul 29, 2026. The company reported -CHF0.168 earnings per share for the quarter, beating the consensus estimate of -CHF0.2 by CHF0.032.
Is Teladoc overvalued?
According to Wall Street analysts Teladoc’s price is currently Overvalued.
Does Teladoc pay dividends?
Teladoc does not currently pay dividends.
What is Teladoc’s EPS estimate?
Teladoc’s EPS estimate is -0.17.
How many shares outstanding does Teladoc have?
Currently, no data Available
What happened to Teladoc’s price movement after its last earnings report?
Teladoc reported an EPS of -CHF0.168 in its last earnings report, beating expectations of -CHF0.2. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Teladoc?
Currently, no hedge funds are holding shares in CH:4LL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teladoc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF6.26 (-16.79% Downside)
CHF6.26 (-16.79% Downside)
Blogger Sentiment
Bullish
CH:4LL Sentiment 63%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.68%
Trailing 12-Months
Company Description
Teladoc
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
4LL Company Deck
4LL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: clear strength and margin expansion in Integrated Care, meaningful product and AI-driven innovation (Teladoc 1 and Pulse), strong liquidity and disciplined cost actions. Offsetting these positives were material near-term challenges in BetterHelp as the business transitions from cash-pay to an insurance/in-network model — accelerated declines in cash-pay users, provider capacity constraints that limited insurance conversion, and a downward revision to consolidated revenue guidance. Management has taken decisive actions (national insurance rollout, provider recruitment/activation initiatives, lower ad spend) to address the issues, but execution risk and timing remain. Overall, the results show operational progress in core businesses and constructive steps to fix the BetterHelp transition, balanced by meaningful short-term revenue pressure and uncertainty in that segment.View all CH:4LL earnings summaries4LL Revenue Breakdown
56.44% Teladoc Health Integrated Care
43.56% BetterHelp
4LL Stock 12 Month Forecast
Average Price Target
CHF6.26
▼(-16.79% Downside)
Technical Analysis
American Well
―
Doximity
―
VSee Health
―
Hinge Health, Inc. Class A
―
Omada Health, Inc.
―